Literature DB >> 25904061

Platelets from flowing blood attach to the inflammatory chemokine CXCL16 expressed in the endothelium of the human vessel wall.

S Meyer Dos Santos, K Blankenbach, K Scholich, A Dörr, N Monsefi, M Keese, B Linke, H Deckmyn, K Nelson, S Harder1.   

Abstract

Endothelial chemokine CXC motif ligand 16 (CXCL16) expression is associated with atherosclerosis, while platelets, particularly those attaching to atherosclerotic plaque, contribute to all stages of atherosclerotic disease. This investigation was designed to examine the role of CXCL16 in capturing platelets from flowing blood. CXCL16 was expressed in human atherosclerotic plaques, and lesion severity in human carotid endarterectomy specimens was positively correlated with CXCL16 levels. CXCL16 expression in plaques was co-localised with platelets deposited to the endothelium. Immobilised CXCL16 promoted CXCR6-dependent platelet adhesion to the human vessel wall, endothelial cells and von Willebrand factor during physiologic flow. At low shear, immobilised CXCL16 captured platelets from flowing blood. It also induced irreversible platelet aggregation and a rise in intra-platelet calcium levels. These results demonstrate that endothelial CXCL16's action on platelets is not only limited to platelet activation, but that immobilised CXCL16 also acts as a potent novel platelet adhesion ligand, inducing platelet adhesion to the human vessel wall.

Entities:  

Keywords:  Adhesion; adhesion receptors; chemokines; platelets; vascular inflammation

Mesh:

Substances:

Year:  2015        PMID: 25904061     DOI: 10.1160/TH14-11-0911

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Cytokines associated with immune response in atherosclerosis.

Authors:  Jiqing Ma; Jianhua Luo; Yudong Sun; Zhiqing Zhao
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Allelic Variation in CXCL16 Determines CD3+ T Lymphocyte Susceptibility to Equine Arteritis Virus Infection and Establishment of Long-Term Carrier State in the Stallion.

Authors:  Sanjay Sarkar; Ernest Bailey; Yun Young Go; R Frank Cook; Ted Kalbfleisch; John Eberth; R Lakshman Chelvarajan; Kathleen M Shuck; Sergey Artiushin; Peter J Timoney; Udeni B R Balasuriya
Journal:  PLoS Genet       Date:  2016-12-08       Impact factor: 5.917

Review 3.  Whole Blood Based Multiparameter Assessment of Thrombus Formation in Standard Microfluidic Devices to Proxy In Vivo Haemostasis and Thrombosis.

Authors:  Isabella Provenzale; Sanne L N Brouns; Paola E J van der Meijden; Frauke Swieringa; Johan W M Heemskerk
Journal:  Micromachines (Basel)       Date:  2019-11-16       Impact factor: 2.891

Review 4.  Inflammatory Chemokines in Atherosclerosis.

Authors:  Selin Gencer; Bryce R Evans; Emiel P C van der Vorst; Yvonne Döring; Christian Weber
Journal:  Cells       Date:  2021-01-25       Impact factor: 6.600

Review 5.  Inflammatory Mediators in Atherosclerotic Vascular Remodeling.

Authors:  Bryce R Evans; Anaïs Yerly; Emiel P C van der Vorst; Iris Baumgartner; Sarah Maike Bernhard; Marc Schindewolf; Yvonne Döring
Journal:  Front Cardiovasc Med       Date:  2022-05-04

6.  Platelet SR-PSOX/CXCL16-CXCR6 Axis Influences Thrombotic Propensity and Prognosis in Coronary Artery Disease.

Authors:  Tianyun Guan; Frederic Emschermann; Christoph Schories; Patrick Groga-Bada; Peter Martus; Oliver Borst; Meinrad Gawaz; Tobias Geisler; Dominik Rath; Madhumita Chatterjee
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

7.  CXCL16 regulates cisplatin-induced acute kidney injury.

Authors:  Hua Liang; Zhengmao Zhang; Liqun He; Yanlin Wang
Journal:  Oncotarget       Date:  2016-05-31

Review 8.  Molecular Drivers of Platelet Activation: Unraveling Novel Targets for Anti-Thrombotic and Anti-Thrombo-Inflammatory Therapy.

Authors:  Madhumita Chatterjee; Agnes Ehrenberg; Laura Mara Toska; Lisa Maria Metz; Meike Klier; Irena Krueger; Friedrich Reusswig; Margitta Elvers
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.